Pfizer Vaccine Safe, Effective in Juvenile Inflammatory Disease
A multi‑center trial published this week confirms that Pfizer's mRNA COVID‑19 vaccine is both safe and effective for children suffering from juvenile inflammatory diseases such as juvenile idiopathic arthritis and inflammatory bowel disease. The study tracked 312 participants aged 5‑17, observing no vaccine‑related serious adverse events and antibody responses that mirrored those of age‑matched healthy peers. Immunogenicity persisted through six months, and disease activity scores remained stable post‑vaccination. The results were peer‑reviewed in *Pediatrics* and add robust data to the limited evidence base for immunocompromised pediatric populations.
How Nanomedicine Gets Inside Your Cells and Treats You From the Inside Out
Nanomedicine is moving from concept to clinic as researchers use lipid‑nanoparticle carriers to deliver synthetic mRNA and siRNA directly into patient cells. The approach lets liver cells produce missing proteins such as factor VIII for hemophilia A, while silencing harmful proteins like...
Trump Administration to Review Ibogaine for PTSD, Opens Federal Research Path
President Trump is set to sign an executive order this week that will direct federal agencies to study ibogaine, a psychedelic currently classified as a Schedule I drug, for its potential to treat PTSD and traumatic brain injury. The move does...
UCSF Pushes Forward Treg Cell Therapy to Prevent Type 1 Diabetes
UCSF scientists are advancing a regulatory T‑cell (Treg) therapy aimed at preventing type 1 diabetes, leveraging the center’s legacy of biomarker discovery and the 2022 FDA‑approved drug Teplizumab. The approach could reduce reliance on lifelong insulin and immunosuppressive drugs, a key...
UCB to Acquire Neurona Therapeutics for Up to $1.15 Billion, Boosting Epilepsy Portfolio
Belgian biopharma UCB announced a deal to buy U.S.‑based Neurona Therapeutics for up to $1.15 billion, with $650 million paid upfront and up to $500 million in milestones. The acquisition strengthens UCB’s epilepsy franchise and is expected to lift adjusted EBITDA into the...
Endobronchial Valves Offer New Hope for Severe COPD Patients
Pulmonx's Zephyr endobronchial valves, approved by the FDA in 2018, are giving severe COPD patients a minimally invasive way to regain lung function. More than 40,000 people worldwide have received the treatment, and a New Jersey patient recently reported walking...
Storm Therapeutics Secures $56 Million Series C to Push METTL3 Cancer Drug Into Phase 2
Storm Therapeutics announced a $56 million Series C financing led by Pfizer Ventures, M Ventures and other pharma‑backed investors. The cash will fund a Phase 2 monotherapy study of STC‑15, a first‑in‑class METTL3 inhibitor, in hard‑to‑treat sarcomas. The round signals growing confidence in epitranscriptomic...
Design‑First Protein Engineering Delivers Round‑One Success
Protein engineering has a dirty secret: most of the work is in the lab, not the algorithm. You design, you test, most variants fail, you iterate for months. Scala Biodesign's bet is that the design layer can do most of that...
OpenAI Launches GPT‑Rosalind, a Life‑sciences LLM for Drug Discovery
OpenAI unveiled GPT‑Rosalind, a domain‑specific large language model built for life‑science research, and made it available as a research preview in ChatGPT, Codex and its API. The company said the model will help biotech and pharmaceutical teams accelerate early‑stage discovery,...
STAT's Live AACR Coverage: Newsletter, Event, Recap
A heads up: starting Sunday, and through the beginning of next week, STAT is going to be taking the annual meeting of the American Association of Cancer Research by storm. This is one of the best venues for spotting new ideas...
France Leads Approval of IV Ketamine for Suicidal Crises
Scientists test if ketamine has antidepressant effects under anesthesia; France is the first to approve IV ketamine for severe suicidal crisis https://t.co/s7W7YlAOMr
GPT-Rosalind: The AI Scientist Changing Drug Discovery 🧬🚀
OpenAI unveiled GPT‑Rosalind, a frontier‑reasoning model built specifically for live scientific research in biology, drug discovery and translational medicine. Unlike a generic chatbot, it is engineered to think like a scientist, parsing complex protein, gene, chemical reaction and disease biology...
Major UKHSA Study Finds Maternal RSV Vaccination Reduces Infant Hospitalization Risk by More Than 80%
Researchers from the UK Health Security Agency presented the largest real‑world evaluation of maternal RSV immunisation, showing that infants whose mothers received the bivalent Prefusion F vaccine at least two weeks before delivery experienced an 81.3% drop in RSV‑related hospitalisations. The...
Viral Immunity and Behavior Sustain Low Mpox Rates
A new Nature Communications study reveals that Los Angeles’ persistent, low‑level mpox incidence is driven by repeated viral introductions and a return to pre‑outbreak sexual behavior patterns. Genomic sequencing traced multiple independent importations rather than a single endemic chain, while mathematical...
New PARP Inhibitor Resistance Mechanisms Found in Ovarian Cancer
A recent British Journal of Cancer study uncovers drug‑specific resistance mechanisms to PARP inhibitors in ovarian cancer, highlighting alterations in PARP trapping, replication‑fork protection, and chromatin‑remodeling. The research shows that resistance is not limited to homologous recombination restoration but involves...
Mammary Organoid Depot Enables Post-Surgery Chemo, Regeneration
Researchers have created a mammary organoid‑based depot that delivers a pH‑responsive doxorubicin prodrug directly to the surgical site while simultaneously regenerating breast tissue. The engineered organoids mimic lactation, loading drug‑laden lipid droplets into milk‑fat globules that are secreted locally, achieving...